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ble disease. The median progression-free survival was 6.33 
months. The median overall survival was 10.8 months. Grade 
3/4 neutropenia and thrombocytopenia were noted in 13 
and 7% of the patients, respectively. Grade 2/3 nonhema-
tologic toxicities were asthenia (54% of patients), diarrhea 
(17%), stomatitis (23%) and hand-foot syndrome (7%). There 
was no treatment-related death. The drugs taken were 
skipped at least once in 45% of the patients and the dose was 
reduced in 26% of them.  Conclusions: The combination of 
FDR gemcitabine and capecitabine in this 3-week cycle is 
safe and seems to have a good activity in advanced biliary 
cancer.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Biliary tract cancers (BTC) are relatively rare tumors 
with a dismal prognosis  [1] . This kind of tumor is more 
likely to occur in patients aged between 50 and 70 years. 
As far as the role of nonsurgical oncologic treatment is 
concerned, the only standard regimen for advanced dis-
ease has recently been established. In fact, the ABC-02 
study, a practice-changing phase III study, recognized the 
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 Abstract 
 Background: This phase II trial was conducted to determine 
the activity and safety of the combination of fixed-dose rate 
(FDR) gemcitabine and capecitabine in metastatic biliary 
tract cancer (BTC) patients.  Methods: Patients with unresect-
able BTC who had pathologically confirmed adenocarcino-
ma, no prior chemotherapy, Eastern Cooperative Oncology 
Group (ECOG) performance status  ^  1 and measurable dis-
ease were enrolled. Treatment consisted of FDR gemcitabine 
at 800 mg/m 2 on days 1 and 8 every 21 days with capecita-
bine administered orally b.i.d. in equal doses (650 mg/m 2 
b.i.d.) for 14 days (28 doses).  Results: Between May 2005 and 
February 2009, 30 patients were enrolled. The median age 
was 67 years (45–76) and there were 14 males. Thirty patients 
were evaluable for response and toxicity. A total of 221 cycles 
were administered (median 7, range 2–16). One patient 
achieved complete response and 7 patients achieved partial 
response, giving an overall response rate of 26.7% in the in-
tention-to-treat population. Twelve patients (40.0%) had sta-
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gemcitabine/cisplatin regimen as the standard of care, 
with a stable disease rate of 81%, progression-free sur-
vival (PFS) of 8 months and median overall survival (OS) 
of 11.7 months. Due to clinical conditions, patients who 
receive palliative chemotherapy are usually treated with 
single-agent gemcitabine or with combination regimens 
including mitomycin or fluoropyrimidines  [2, 3] . Re-
sponse rates with these treatments range from 10 to 35%, 
and median OS time varies between 5 and 12 months  [4] . 
Nevertheless, the small number of published trials and 
the considerable variability in the patients’ clinical char-
acteristics make the data difficult to interpret. Nowadays, 
there is no standard chemotherapy regimen in BTC. Sev-
eral reports have demonstrated that gemcitabine is active 
in BTC  [5–7] . Capecitabine (Xeloda TM ; Hoffmann-La 
Roche, Basel, Switzerland) is an oral fluoropyrimidine 
carbamate that selectively generates 5-FU in tumor tis-
sues. Gemcitabine also appears to modulate the activity 
of 5-fluorouracil (5-FU) in renal and gastrointestinal ma-
lignancies  [8, 9] . Capecitabine offers the possibility of 
continuous tumor exposure to 5-FU by preferential acti-
vation at the tumor, while potentially minimizing the 
 exposure of healthy body tissues to systemic 5-FU  [10,
11] . Moreover, 5-FU has demonstrated activity in BTC 
 [12] . As shown in our phase I study, to enhance the cyto-
toxic activity of gemcitabine, an alternative infusion regi-
men has been explored  [13] . As the active metabolite of 
gemcitabine, 2  ,2  -difluorodeoxycytidine triphosphate 
(dFdCTP), has a long intracellular half-life, a fixed-dose 
rate (FDR) infusion of 10 mg/m 2 /min has been shown to 
lead to maximal intracellular accumulation. In particu-
lar, it has been demonstrated that increasing the infu-
sion time while holding the dose rate constant at 10 mg/
m 2 /min could result in increased intracellular levels of 
dFdCTP, thus enhancing the activity of gemcitabine  [14, 
15] . On the basis of phase I results, the dose of FDR 
 gemcitabine 800 mg/m 2 in 80 min on days 1 and 8 plus 
capecitabine 650 mg/m 2 b.i.d., for 14 consecutive days fol-
lowed by 1 week of rest, is a recommended schedule that 
we used in this study. This is a phase II study evaluating 
toxicity, response, and survival associated with using a 
combination of FDR gemcitabine and capecitabine to 
treat patients with unresectable or metastatic BTCs.
 Patients and Methods 
 Eligibility 
 Patients with histologically confirmed unresectable or meta-
static BTC adenocarcinomas, including those who were at least 18 
years old and who had an Eastern Cooperative Oncology Group 
(ECOG) performance status  ^  1, were considered suitable for the 
study. The following hematologic and chemistry parameters were 
recommended: absolute neutrophil count 1,500/mm 3 , platelet 
count 100,000/mm 3 , hemoglobin 10.0 g/100 ml, preserved renal 
function (serum creatinine 1.6 mg/dl, normal creatinine clear-
ance), and hepatic function (total bilirubin 1.5 mg/dl, aspartate 
aminotransferase and alanine aminotransferase 2.5 ! normal 
without hepatic metastasis and 4 ! normal with hepatic metasta-
sis, serum alkaline phosphatase  ! 2.5 ! the upper limit of normal 
or  ! 5 ! the upper limit of normal if liver metastases were present 
or  ! 10 ! the upper limit of normal if bone metastases were pres-
ent). A basal cardiac function evaluation was required.
 Major exclusion criteria included radiotherapy or chemora-
diotherapy treatment within the previous 4 weeks (6 weeks if the 
previous therapy included nitrosourea or mitomycin C). Patients 
previously treated with chemotherapy for metastatic disease were 
excluded. Concomitant use of amiodarone, ketoconazole, itra-
conazole, diltiazem, verapamil, barbiturates, and warfarin was 
not permitted. Pregnant or lactating patients were excluded from 
the study. Patients with significant stomach, small intestine, liver, 
or kidney disease likely to affect drug absorption or metabolism 
were excluded from the study. Other contraindications included 
a history of coagulopathy or brain or other central nervous system 
metastases. Patients with any history of a previous malignancy 
diagnosed within 5 years were also excluded, with the exception 
of basal cell carcinoma or skin and cervical carcinoma in situ. Ad-
ditionally, patients were excluded if adequate follow-up was not 
possible (geographic difficulties, no compliance with necessary 
clinical-instrumental investigations, etc.).
 All patients were required to provide written informed con-
sent before initiation of treatment after a complete and clear ex-
planation. Approval of the local ethics committee was obtained. 
The trial was conducted in accordance with the declaration of 
Helsinki.
 Treatment and Dose Modifications 
 Capecitabine (650 mg/m 2 b.i.d.) was administered orally
twice a day for 14 consecutive days followed by 1 week of rest. It 
was supplied as film-coated Xeloda tablets in two dosage strengths, 
150-mg and 500-mg tablets, administered in nonfasting condi-
tions and swallowed with water. Gemcitabine (Gemzar TM ) was giv-
en at an FDR dose of 800 mg/m 2 in 80 min on days 1 and 8 of each 
cycle. The drug was prepared for administration according to the 
directions in the package. Cycles were repeated every 21 days. All 
patients had their medical history taken and had a full physical 
examination with radiologic and laboratory evaluations. History, 
physical examination, and laboratory tests were repeated on day 1 
of each cycle of therapy. Prophylactic administration of recombi-
nant human granulocyte colony-stimulating factor was not al-
lowed. In cases where the patient had grade 3 or 4 afebrile neutro-
penia, subsequent cycles were repeated with recombinant human 
granulocyte colony-stimulating factor, and capecitabine and gem-
citabine doses were reduced by 25%. In cases of grade 3 or 4 throm-
bocytopenia lasting more than 7 days, the doses of both drugs were 
also reduced by 25%. The doses of capecitabine were reduced by 
25% in cases of grade 3 or 4 diarrhea or hand-foot syndrome.
 Efficacy and Safety Evaluation 
 Tumor assessment according to RECIST criteria was per-
formed at 9-week intervals by the investigators  [16] . Tumor lesions 
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were assessed by computed tomography scanning, X-rays or mag-
netic resonance imaging. Responding patients or those with sta-
ble disease (SD;  1 3 months) could continue treatment until pro-
gression of disease (PD), unacceptable toxicity or their decision to 
stop. PFS was calculated as the time from the time of inclusion in 
the study to the first record of PD or the date of death if the patient 
died before PD was demonstrated. Survival was monitored every 
3 months after the patient completed treatment. Safety was mon-
itored during the study and for 28 days after the last cycle treat-
ment. Adverse events were graded according to the National Can-
cer Institute of Canada-Common Toxicity Criteria (NCI-CTC) 
 [17] . PFS and OS were analyzed by the Kaplan-Meier method. 
Those patients who did not receive at least one dose of study med-
ication or for whom no follow-up safety information was available 
were excluded.
 Statistical Analysis 
 The Simon optimal two-stage design was chosen for sample 
size calculation. The expected number of patients for accrual in 
this study was calculated to reject a 10% response rate in favor of 
a target response rate of 30%. This condition allows a significance 
level of 0.05 with a statistical power of 90%. The preliminary ac-
tivity of this new combination will be assessed enrolling 9 pa-
tients. If there was  ! 1 response, accrual needed to be terminated. 
Otherwise, 21 additional patients need to be entered in the second 
stage to achieve a target sample size of 30 evaluable patients for 
tumor response. If more than 4 responses were observed in these 
30 patients, further assessment could be suggested. RECIST cri-
teria were considered for the evaluation of response. Kaplan-Mei-
er survival curves were generated based on the PFS and OS data 
and analyzed by the log-rank statistic.
 Results 
 Patient Characteristics 
 Thirty patients were enrolled between May 2005 and 
February 2009. The median age was 67.0 years (range 45–
76); there were 17 (55%) females and 14 (45%) males. All 
patients completed the first two cycles of therapy and 
were, therefore, assessable for toxicity and for efficacy. 
ECOG performance status was 0 in 24 (77%) of patients 
and 1 in the other 7 (23%). Seven (23%) patients needed 
biliary drainage. The distribution of primary cancer was: 
gallbladder in 13 (42%) patients, ampulla of Vater in 2 
(6%) patients, intrahepatic cholangiocarcinoma in 9 
(29%) patients and extrahepatic bile duct in 7 (23%) pa-
tients. A total of 221 cycles were administered; the me-
dian number of cycles for a patient was 7.0 (range 2–16). 
The median follow-up was 22.3 months. As shown in  ta-
ble 1 , the majority of patients (97%) had stage IV disease 
and the most commonly affected metastatic sites were 
liver (81%) and abdominal lymph nodes (35%).
Table 1.  Patient characteristics
Characteristic Number of patients
Evaluable patients 30 (97%)
Gender
Male
Female
14 (45%)
17 (55%)
Age, years 
Median (range) 67 (45–76)
ECOG performance status
0
1
24 (77%)
7 (23%)
Disease at presentation
Locally advanced
Metastatic disease
1 (3%)
30 (97%)
Primary disease
Gallbladder
Ampulla of Vater
Intrahepatic cholangiocarcinoma
Extrahepatic bile duct cancer
13 (42%)
2 (6%)
9 (29%)
7 (23%)
Metastatic sites 
Median (range) 1 (0–5)
Sites of metastatic disease
Liver
Lymph nodes
Peritoneum
Lung
Others
25 (81%)
11 (35%)
2 (6%)
1 (3%)
4 (13%)
Table 2.  Treatment-related toxicity
Toxicity N umber of patients (n = 30)
grade 1 grade 2 grade 3 grade 4
Hematologic
Neutropenia 1 (3%) 9 (30%) 3 (10%) 1 (3%)
Leukopenia 3 (10%) 3 (10%) 2 (7%)
Thrombocytopenia 3 (10%) 4 (13%) 2 (7%)
Anemia 14 (47%) 5 (16%)
Nonhematologic
Nausea 13 (43%) 6 (20%)
Diarrhea 9 (30%) 3 (10%) 2 (7%)
Stomatitis 6 (20%) 6 (20%) 1 (3%)
Elevated AST 4 (13%)
Fatigue 8 (27%) 11 (37%) 5 (17%)
HFS 3 (10%) 2 (7%)
Tox icity was graded according to the second version of the 
Common Toxicity Criteria of the National Cancer Institute.
AST = Aspartate aminotransferase; HFS = hand-foot syndrome.
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 Safety 
 Table 2 summarizes the observations on toxicity. Non-
hematologic adverse events (G2 percentage/G3 percent-
age) were: nausea (20/0), hand-foot syndrome (7/0), gen-
eral weakness (37/17), stomatitis (20/3), and diarrhea 
(10/7). One patient (3%) experienced G4 nonfebrile neu-
tropenia. Grade 3 neutropenia, anemia, and thrombocy-
topenia were present in 10, 0 and 7% of patients, respec-
tively. Eight patients (27%) had reduced drug doses for 
neutropenia (2), thrombocytopenia (1), diarrhea (2), gen-
eral weakness (2), and hand-foot syndrome (1). Fourteen 
patients (47%) needed to delay chemotherapy because of 
neutropenia (5). No deaths occurred during the study 
which could be attributed to toxicity.
 Efficacy 
 The median duration of treatment for all patients was 
143 days (range 34–390 days). Seven (23%) of 30 evaluated 
patients (1 patient excluded for causes not associated with 
the tumor) obtained a partial response, 1 patient (3%) had 
a complete response, and 12 patients (40%) had SD obtain-
ing tumor control (complete response + partial response 
+ SD) of 66%. Ten patients (33%) had PD. The median PFS 
was 6.33 months. PFS were 52 and 31% at 6 months and 1 
year, respectively ( fig. 1 ). The subgroup analysis showed a 
PFS of 14.2, 8 and 2.5 months in intrahepatic biliary tract 
(VBI), extrahepatic biliary tract (VBE) and in gallbladder, 
respectively ( fig. 2 ). The median OS for the entire popula-
tion was 10.8 months ( fig. 3 ). At 6 months, 1 year and 2 
years, 71, 43 and 32% of patients were alive, respectively. 
Efficacy data are shown in  table 3 .
 Discussion 
 At the moment, there is no standard chemotherapy 
regimen for advanced biliary cancer. Historically, che-
motherapy had little impact on the natural history of this 
disease. There are several reasons for this: a lack of active 
agents, the overall morbidity of treatment and conse-
Table 3.  Therapeutic results
Result Number of patients
Complete response 1 (3%)
Partial response 7 (23%)
SD 12 (40%)
PD 10 (33%)
0
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Median PFS 6.33 months
PFS at 6 months 52%
PFS at 1 year 31%
 Fig. 1. PFS: median, at 6 months, and at 1 year. 
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 Fig. 3. OS: median, at 6 months, and at 1 and 2 years. 
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 Fig. 2. PFS for primary sites: VBI, VBE and gallbladder. 
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quently reduced dose intensity, and the grouping togeth-
er of different cancer types with different biologies. Old-
er chemotherapy combinations with 5-fluorouracil have 
demonstrated response rates of less than 15%. To our 
knowledge, only one published randomized study has 
shown an improvement in quality of life for biliary cancer 
patients treated with 5-fluorouracil-based chemotherapy 
versus best supportive care, although no difference in OS 
was observed  [18] . In  table 4 , the principal phase II stud-
ies are summarized, where regimens containing new 
agents such as gemcitabine, capecitabine, and oxaliplatin 
have demonstrated objective responses in 20–45% of pa-
tients and a median survival of 8–14 months. The recent 
approval of numerous targeted agents in a variety of sol-
id tumors and hematologic malignancies has clearly 
demonstrated the clinical efficacy of such agents. How-
Table 4.  Recent clinical trials of biliary cancer
Author, year, Ref. No. Regimen No. Tumor sites RR, % OS, months
Gallardo, 2001 [20] gemcitabine 26 gallbladder 35 7.5
Kuhn, 2002 [21] gemcitabine/docetaxel 43 gallbladder + bile duct 9 11
Taieb, 2002 [22] cisplatin/5-FU 29 gallbladder + bile duct 34 9.5
Nehls, 2003 [23] capecitabine/oxaliplatin 29 gallbladder + bile duct 23 9.5
Reyes-Vidal, 2003 [24] gemcitabine/cisplatin 44 gallbladder 45 7
Patt, 2004 [25] capecitabine 26 gallbladder + bile duct 17 7
Eng, 2004 [26] fixed-dose gemcitabine 15 bile duct 0 5
Kornek, 2004 [27] mitomycin/gemcitabine vs.
mitomycin/capecitabine
51 bile duct 20
31
6.7
9 (P no sign)
Knox, 2005 [28] gemcitabine/capecitabine 45 gallbladder + bile duct 30 14
Rao, 2005 [29] 5-FU/leucovorin vs.
ECF
54 bile duct 19
15
12
9 (P no sign)
Ducreux, 2005 [30] 5-FU vs.
5-FU/cisplatin 
58 bile duct 7
19
5
8 (P no sign)
Julka, 2006 [31] gemcitabine/oxaliplatin 20 gallbladder 36.7 ND
Lee, 2006 [32] gemcitabine/oxaliplatin 24 bile duct 21 9.3
Philip, 2006 [33] erlotinib 42 bile duct 7 ND
Manzione, 2007 [34] gemcitabine/oxaliplatin 34 gallbladder + bile duct 41 10
Hong, 2007 [35] capecitabine/cisplatin 32 gallbladder + bile duct 40.6 12.4
Riechelmann, 2007 [36] gemcitabine/capecitabine 75 gallbladder + bile duct 29 12.7
Andre, 2008 [37] gemcitabine/oxaliplatin 45 gallbladder + bile duct 33 8.3
Im, 2008 [38] S1/cisplatin 51 gallbladder + bile duct 30 8.7
Furuse, 2008 [39] S1 40 gallbladder + bile duct 35 9.4
Meyerhardt, 2008 [40] gemcitabine/cisplatin 30 gallbladder + bile duct 21 9.7
Valle, 2009 [41] gemcitabine vs.
gemcitabine/cisplatin
86 gallbladder + bile duct 15
24
ND
Wagner, 2009 [42] gemcitabine/oxaliplatin/5-FU 37
35
bile duct
gallbladder 
19
23
10
9.9
Sasaki, 2009 [43] S1/gemcitabine 35 gallbladder + bile duct 34.3 11.6
Kim, 2009 [44] gemcitabine/oxaliplatin 40 gallbladder + bile duct 15 8.5
Ramanathan, 2009 [45] lapatinib 17 bile duct 0 5.2
Yamashita, 2010 [46] gemcitabine/cisplatin/5-FU 21 bile duct 33.3 18.8
Sharma, 2010 [47] gemcitabine/oxaliplatin 50 gallbladder 21.2 7.5
Jang, 2010 [48] gemcitabine/oxaliplatin 53 gallbladder + bile duct 18.9 8.3
No. = Number of enrolled patients; R R = response rate; 5-FU = 5-fluorouracil; ECF = epirubicin, cisplatin, 5-fluorouracil; P no
sign = not statistically significant; ND = not done.
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ever, the overall modest activity of these agents in ‘or-
phan’ tumors such as BTC emphasizes the need for novel 
and more effective medical treatment options such as 
combinations of targeted agents with cytotoxic drugs or 
with other novel anticancer drugs. In our study, the com-
bination of FDR gemcitabine and capecitabine demon-
strated an interesting activity and a favorable safety in 
patients with advanced and/or metastatic BTC. Despite 
the usual limitation of cross-study comparisons, these 
findings compare favorably with results previously re-
ported for 5-FU/gemcitabine combinations in patients 
with advanced BTC. In addition to antitumor activity, 
safety is a critically important target for the choice of new 
treatment combinations. Our combination regimen has 
the advantage of convenience and practicability over con-
tinuous intravenous 5-FU plus either gemcitabine or cis-
platin, and has a clear potential to reduce healthcare re-
source expenditure. This is because capecitabine is ad-
ministered orally and avoids the complications related to 
the use of an implanted catheter required for the contin-
uous intravenous administration of 5-FU. In our experi-
ence, the toxicity profile is acceptable especially when 
compared with the toxicities reported in comparable 
studies. Grade 3 neutropenia and asthenia were reported 
in 10 and 16%, respectively, and these data are superim-
posed with the data reported in the literature. Biliary tu-
mors can occur anywhere in the hepatobiliary system 
and are often classified according to location. In the pres-
ent study, cholangiocarcinoma (VBI + VBE) appeared to 
respond better than gallbladder carcinoma (PFS: 8.7 vs. 
2.5 months, p = 0.005), obtaining a major OS (25 vs. 6 
months, p = 0.001), even if the interpretation of data is 
difficult because of the relatively small number of pa-
tients and the different biological and prognostic behav-
ior of the single isotypes.
 Conclusions 
 Further research in this area should be directed at find-
ing the best cytotoxic agent for a combination with 
capecitabine or gemcitabine or altering the dose intensity 
or route of administration in advanced BTC. Convention-
al chemotherapeutic drugs have achieved only modest re-
sults in patients with BTC. Therefore, innovative thera-
peutic approaches are needed to obtain significant results 
in this type of patients. The first standard of care has been 
proposed at ASCO 2009  [19] . In fact, the combination of 
cisplatin and gemcitabine has been shown to be more ef-
fective than gemcitabine alone in a multicenter random-
ized phase III trial  [2] , and new phase III trials evaluating 
a different combination of chemotherapy are needed. Due 
to the small number of patients and the inclusion of all 
biliary types (ampullary, gallbladder, bile duct) in this 
study, these results cannot be translated in clinical prac-
tice. A larger randomized phase III trial of our combina-
tion regimen compared with gemcitabine plus cisplatin 
needs to be conducted to validate the efficacy of FDR gem-
citabine plus capecitabine in metastatic/advanced BTC 
patients. Several trials are ongoing with the aim to explore 
the activity of the combination of chemotherapeutics with 
different targeted drugs inhibiting different pathways. 
The results of the ongoing trials are keenly awaited to def-
initely identify the most effective strategy in BTC.
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